SenesTech Announces Closing of Warrant Exercise for $4.4 Million in Gross Proceeds

Rhea-AI Summary

SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced the closing of a warrant exercise transaction that generated $4.4 million in gross proceeds. The transaction involved the exercise of existing warrants to purchase 1,458,872 shares of common stock at $2.90 per share.

As part of the transaction, the company issued new unregistered short-term warrants to purchase an additional 1,458,872 shares at $4.15 per share, with a purchase price of $0.125 per warrant. These new warrants expire 15 months after the effective date of the resale registration statement. If fully exercised, the new warrants could generate approximately $6.0 million in additional gross proceeds. H.C. Wainwright served as the exclusive placement agent for the transaction.

The company plans to use the net proceeds for working capital and general corporate purposes.

Positive

• Raised $4.4 million in gross proceeds from warrant exercise
• Potential for additional $6.0 million if new warrants are fully exercised
• Strengthened working capital position

Negative

• Dilution of existing shareholders through warrant exercises
• New warrants issued at relatively low premium ($4.15 vs $2.90)
• No guarantee that new warrants will be exercised

SURPRISE, Ariz., July 1, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), a leader in fertility control for managing animal pest populations, announced today the closing of its previously announced exercise of certain outstanding warrants to purchase an aggregate of 1,458,872 shares of the Company's common stock originally issued by the Company on March 11, 2025, at the existing exercise price of $2.90 per share.

H.C. Wainwright acted as the exclusive placement agent for the transaction.

As consideration for the exercise of such existing warrants for cash, the Company issued new unregistered short-term warrants to purchase up to an aggregate of 1,458,872 shares of common stock at an exercise price of $4.15 per share at a purchase price of $0.125 per warrant in a private placement priced at-the-market under Nasdaq rules. The new short-term warrants are exercisable immediately and expire fifteen months following the effective date of the resale registration statement registering the shares of common stock issuable upon exercise of the short-term warrants.

The aggregate gross proceeds from the exercise of the existing warrants were approximately $4.4 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential gross proceeds from the new short-term warrants, if fully exercised on a cash basis, will be approximately $6.0 million. No assurance can be given that any of the new short-term warrants will be exercised. The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes.

The resale of the shares of common stock issuable upon the exercise of the existing warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333-288097).

The new short-term warrants related to the warrant inducement transaction have not been registered under the Securities Act of 1933, as amended, or under applicable state securities laws. Accordingly, the new short-term warrants and the shares of common stock issuable upon the exercise of the new short-term warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and such applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About SenesTech

We are committed to improving the health of the world by humanely managing animal pest populations through our expertise in fertility control. We invented ContraPest®, the only U.S. EPA-registered contraceptive for male and female rats, as well as Evolve™ Rat and Evolve™ Mouse, EPA-designated minimum risk contraceptives for rodents, reflecting our mission to provide products that are proactive, safe and sustainable. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. We strive for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable.

For more information, visit https://senestech.com. 

Safe Harbor Statement

 This press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, the following: the intended use of proceeds from the offering and the exercise of the new short-term warrants prior to their expiration.  Forward-looking statements may describe future expectations, plans, results or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, market and other conditions, the successful commercialization of our products, market acceptance of our products, regulatory approval and regulation of our products and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT:
Investor Relations: Robert Blum, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.com 

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143

View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-announces-closing-of-warrant-exercise-for-4-4-million-in-gross-proceeds-302496227.html

SOURCE SenesTech, Inc.

FAQ

How much did SenesTech (SNES) raise from the warrant exercise in July 2025?

SenesTech raised $4.4 million in gross proceeds from the exercise of warrants at $2.90 per share.

What is the exercise price of SenesTech's new short-term warrants issued in July 2025?

The new short-term warrants have an exercise price of $4.15 per share with a purchase price of $0.125 per warrant.

How many shares are involved in SenesTech's July 2025 warrant transaction?

The transaction involved 1,458,872 shares from existing warrant exercises and new warrants to purchase an additional 1,458,872 shares.

How will SenesTech use the proceeds from the July 2025 warrant exercise?

SenesTech plans to use the net proceeds for working capital and general corporate purposes.

When do SenesTech's new short-term warrants expire?

The new short-term warrants expire 15 months following the effective date of the resale registration statement.